← Ablatotech Signals
Immunology SignalsArticle

A putative therapeutic target in rheumatoid arthritis: Q96P31

Re-mining the public omics record reveals an under-explored candidate

Published by Ablatotech Communications
July 11, 2026 · Lead editor: ImmunologyEditor · Staff writer: StaffScienceWriter
Editorial note. This article describes a putative therapeutic target. It is AI-curated commentary, not peer-reviewed research. The target warrants independent experimental validation before clinical translation.

Ablatotech Signals reports today on a putative therapeutic target — Q96P31 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in rheumatoid arthritis.

# Signals Article on Putative Target Q96P31 for Rheumatoid Arthritis

Background

The protein encoded by the putative target Q96P31 has emerged as a candidate of interest in the study of rheumatoid arthritis (RA), a chronic autoimmune disorder characterized by inflammation of the joints and surrounding tissues. Preliminary data suggest that Q96P31 may be involved in the inflammatory processes associated with RA, indicating its potential as a therapeutic target. Given the multifaceted nature of this disease, further investigation into the molecular mechanisms involving this protein is essential for developing effective treatment strategies.

Data-mining rationale

Our analysis utilized the GeoMicroarrayReanalysis approach, cross-referencing reviewed human entries in the UniProt database for "rheumatoid arthritis" against 278 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). The candidate UniProt:Q96P31 was identified as being present in several expression-profiling studies, yet it notably lacks any registered Phase 1 or higher clinical programs. This observation raises questions about its potential role in rheumatoid arthritis and underscores the need for further exploration.

Why prior analyses may have missed this

Many of the GEO datasets analyzed predate the implementation of modern empirical-Bayes statistical methods, such as the limma package, which provides robust multiple-testing correction. Consequently, previous analyses may not have accurately captured the expression dynamics of Q96P31 in the context of rheumatoid arthritis. The absence of rigorous statistical validation could explain why this candidate has not been prioritized in the search for therapeutic targets in RA.

Reasoning for further validation

To substantiate the potential role of Q96P31 in rheumatoid arthritis, several experimental approaches are warranted: 1. Re-analyze the matched GEO datasets using the limma package with a Benjamini-Hochberg false discovery rate (FDR) threshold of < 0.05 to identify differentially expressed genes with greater confidence. 2. Validate the top differentially expressed genes, including Q96P31, by quantitative PCR (qPCR) in an independent cohort of RA patients to confirm expression patterns. 3. Investigate the tissue specificity of Q96P31 expression using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to determine its relevance in joint and synovial tissues. 4. Utilize pathway analysis tools like STRING and OmniPath to contextualize Q96P31 within known biological pathways related to inflammation and rheumatoid arthritis. 5. If validation is achieved, assess the druggability of Q96P31 through databases such as DGIdb and ChEMBL to explore potential therapeutic interventions.

References

  • [UniProt: Q96P31](https://www.uniprot.org/uniprot/Q96P31)
  • [UniProt: Q9NV23](https://www.uniprot.org/uniprot/Q9NV23)
  • [UniProt: O75339](https://www.uniprot.org/uniprot/O75339)
  • [UniProt: Q13568](https://www.uniprot.org/uniprot/Q13568)
  • [UniProt: P50454](https://www.uniprot.org/uniprot/P50454)
  • [NCBI GEO Accession GDS:200313751](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200313751)
  • [NCBI GEO Accession GDS:200312709](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200312709)
  • [NCBI GEO Accession GDS:200267979](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200267979)
  • [NCBI GEO Accession GDS:200186963](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200186963)
  • [NCBI GEO Accession GDS:200242986](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200242986)

References

  1. UniProtKB. Entry Q96P31. The UniProt Consortium. [link]
  2. UniProtKB. Entry Q9NV23. The UniProt Consortium. [link]
  3. UniProtKB. Entry O75339. The UniProt Consortium. [link]
  4. UniProtKB. Entry Q13568. The UniProt Consortium. [link]
  5. UniProtKB. Entry P50454. The UniProt Consortium. [link]
  6. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. [link] PMID: 25605792

© 2026 Ablatotech, Inc. All rights reserved. Published by Ablatotech Communications